161 related articles for article (PubMed ID: 1831682)
21. Recombinant interleukin-2 treatment before and after autologous stem cell transplantation in hematologic malignancies: clinical and immunologic effects.
De Laurenzi A; Iudicone P; Zoli V; De Rosa L; Guglielmetti M; Pescarollo A; Papetti C; Pacilli L; Lapponi P; Petti N
J Hematother; 1995 Apr; 4(2):113-20. PubMed ID: 7633841
[TBL] [Abstract][Full Text] [Related]
22. Generation propagation, and targeting of human CD4+ helper/killer T cells induced by anti-CD3 monoclonal antibody plus recombinant IL-2. An efficient strategy for adoptive tumor immunotherapy.
Nishimura T; Nakamura Y; Takeuchi Y; Tokuda Y; Iwasawa M; Kawasaki A; Okumura K; Habu S
J Immunol; 1992 Jan; 148(1):285-91. PubMed ID: 1345787
[TBL] [Abstract][Full Text] [Related]
23. Infusions of interleukin-1 alpha after autologous transplantation for Hodgkin's disease and non-Hodgkin's lymphoma induce effector cells with antilymphoma cytolytic activity.
Katsanis E; Weisdorf DJ; Xu Z; Dancisak BB; Halet ML; Blazar BR
J Clin Immunol; 1994 May; 14(3):205-11. PubMed ID: 7929695
[TBL] [Abstract][Full Text] [Related]
24. Allogeneic versus autologous bone marrow transplantation for refractory and recurrent low-grade non-Hodgkin's lymphoma.
Verdonck LF; Dekker AW; Lokhorst HM; Petersen EJ; Nieuwenhuis HK
Blood; 1997 Nov; 90(10):4201-5. PubMed ID: 9354692
[TBL] [Abstract][Full Text] [Related]
25. Treatment with recombinant interferon (alpha-2b) early after bone marrow transplantation in patients at high risk for relapse [corrected].
Klingemann HG; Grigg AP; Wilkie-Boyd K; Barnett MJ; Eaves AC; Reece DE; Shepherd JD; Phillips GL
Blood; 1991 Dec; 78(12):3306-11. PubMed ID: 1742491
[TBL] [Abstract][Full Text] [Related]
26. Endogenously generated activated killer cells circulate after autologous and allogeneic marrow transplantation but not after chemotherapy.
Reittie JE; Gottlieb D; Heslop HE; Leger O; Drexler HG; Hazlehurst G; Hoffbrand AV; Prentice HG; Brenner MK
Blood; 1989 Apr; 73(5):1351-8. PubMed ID: 2495037
[TBL] [Abstract][Full Text] [Related]
27. Impaired T and NK cell response of bone marrow and peripheral blood stem cell products to interleukin (IL)-2.
Ozerol I; Ageitos A; Heimann DG; Talmadge JE
Int J Immunopharmacol; 1999 Aug; 21(8):509-21. PubMed ID: 10458540
[TBL] [Abstract][Full Text] [Related]
28. Bone marrow and peripheral blood natural killer cell activity in lymphomas. Its response to IL-2.
Caldera LH; Leon-Ponte M; Acquatella G; Bianco NE; Blanca I
Clin Exp Immunol; 1992 Apr; 88(1):143-8. PubMed ID: 1373350
[TBL] [Abstract][Full Text] [Related]
29. The efficacy of CD3 x CD19 bispecific monoclonal antibody (BsAb) in a clonogenic assay: the effect of repeated addition of BsAb and interleukin-2.
Haagen IA; Geerars AJ; de Lau WB; Bast BJ; de Gast BC
Blood; 1995 Jun; 85(11):3208-12. PubMed ID: 7538821
[TBL] [Abstract][Full Text] [Related]
30. Two populations of CD56 (Leu-19)+/CD16+ cells in bone marrow transplant recipients.
Gottschalk LR; Bray RA; Kaizer H; Gebel HM
Bone Marrow Transplant; 1990 Apr; 5(4):259-64. PubMed ID: 1692496
[TBL] [Abstract][Full Text] [Related]
31. Increased proliferation, lytic activity, and purity of human natural killer cells cocultured with mitogen-activated feeder cells.
Rabinowich H; Sedlmayr P; Herberman RB; Whiteside TL
Cell Immunol; 1991 Jul; 135(2):454-70. PubMed ID: 1709827
[TBL] [Abstract][Full Text] [Related]
32. Expansion of Philadelphia chromosome-negative CD3(+)CD56(+) cytotoxic cells from chronic myeloid leukemia patients: in vitro and in vivo efficacy in severe combined immunodeficiency disease mice.
Hoyle C; Bangs CD; Chang P; Kamel O; Mehta B; Negrin RS
Blood; 1998 Nov; 92(9):3318-27. PubMed ID: 9787169
[TBL] [Abstract][Full Text] [Related]
33. Autologous bone marrow transplantation followed by interleukin-2 in children with advanced leukemia: a pilot study.
Meloni G; Foà R; Tosti S; Vignetti M; Mancini F; Guarini A; Marchis D; Gavosto F; Mandelli F
Leukemia; 1992 Aug; 6(8):780-5. PubMed ID: 1640729
[TBL] [Abstract][Full Text] [Related]
34. Relation between the increase of circulating CD3+ CD57+ lymphocytes and T cell dysfunction in recipients of bone marrow transplantation.
Izquierdo M; Balboa MA; Fernández-Rañada JM; Figuera A; Torres A; Iriondo A; López-Botet M
Clin Exp Immunol; 1990 Oct; 82(1):145-50. PubMed ID: 1698579
[TBL] [Abstract][Full Text] [Related]
35. Cytological characteristics of human glioma-infiltrating lymphocytes stimulated with recombinant interleukin 2 and an anti-CD3 antibody.
Kikuchi T; Watanabe M; Ohno T
Jpn J Cancer Res; 1991 Mar; 82(3):339-45. PubMed ID: 1827092
[TBL] [Abstract][Full Text] [Related]
36. Lymphokine-activated killer cytotoxicity and lymphocyte subpopulations in patients with acute leukemia.
Parrado A; Casares S; Rodríguez-Fernández JM
Leuk Res; 1994 Nov; 18(11):815-22. PubMed ID: 7526078
[TBL] [Abstract][Full Text] [Related]
37. Preservation of lymphokine-activated killer activity following T cell depletion of human bone marrow.
Drobyski WR; Piaskowski V; Ash RC; Casper JT; Truitt RL
Transplantation; 1990 Oct; 50(4):625-32. PubMed ID: 1699309
[TBL] [Abstract][Full Text] [Related]
38. Culture of normal and leukemic bone marrow in interleukin-2: analysis of cell activation, cell proliferation, and cytokine production.
Klingemann HG; Neerunjun J; Schwulera U; Ziltener HJ
Leukemia; 1993 Sep; 7(9):1389-93. PubMed ID: 8371589
[TBL] [Abstract][Full Text] [Related]
39. Bone marrow transplantation after failure of autologous transplant for non-Hodgkin's lymphoma.
de Lima M; van Besien KW; Giralt SA; Khouri IF; Mehra R; Andersson BS; Przepiorka D; Gajewski JL; Korbling M; Champlin RE
Bone Marrow Transplant; 1997 Jan; 19(2):121-7. PubMed ID: 9116608
[TBL] [Abstract][Full Text] [Related]
40. IL-4 regulation of a protein kinase C independent pathway for the generation of alpha CD3-induced activated killer cells.
Ting CC; Hargrove ME
Cell Immunol; 1992 Mar; 140(1):130-44. PubMed ID: 1531452
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
